NASDAQ: ODTXOdyssey Therapeutics Inc Stock
$16.42
Updated May 8, 2026
ODTX Price
$16.42
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$15.35
52 Week High
$20.30
P/E
-0.34x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$2.98M
Earnings
-$148.65M
Gross Margin
100%
Operating Margin
-5,025.44%
Profit Margin
-4,994.9%
Debt to Equity
-0.11
Operating Cash Flow
-$129M
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ODTX Overview
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ODTX's potential to beat the market
- ODTX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ODTX
RankedUnranked of 458
RankedUnranked of 458
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $225.79 | A | |
| $48.16 | A | |
| $7.49 | A |
Be the first to know about important ODTX news, forecast changes, insider trades & much more!
ODTX News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ODTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ODTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ODTX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ODTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ODTX due diligence checks available for Premium users.
Valuation
ODTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.34x
Industry
16.32x
Market
23.73x
ODTX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
ODTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ODTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$269.8M
Liabilities
$54.5M
Debt to equity
-0.11
ODTX's short-term assets ($190.66M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ODTX's short-term assets ($190.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ODTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ODTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ODTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Odyssey Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.